Skip Navigation

University of Michigan Medical Center

Location

University of Michigan Medical Center
Blood and Marrow Transplant Program
1500 East Medical Center Drive, SPC 5271
F4826 UH South
Ann Arbor, MI 48109-5271
Direct phone: (734) 232-7587
Toll-free: (800) 865-1125

Total transplants by cell source

From January 1, 2017 to December 31st, 2018
  • Marrow: 64
  • PBSC: 156
  • Cord Blood: 11
  • Autologous (PBSC or Marrow): 254
Performs adult; pediatric transplants

Overview

The University of Michigan’s BMT program averages 250 transplants each year-making us one of the largest programs in the state of Michigan. Our program is patient-focused, research-driven and internationally recognized for expertise in transplantation. Our Adult & Pediatric program has maintained FACT accreditation for the past 20 years and maintains a multidisciplinary approach to treating our BMT patients. Our medical teams are comprised of physician, nurse coordinators, physician assistants, social work, and pharmacists working together with insurance and financial teams to provide each patient the best care all in one hospital. In addition, we also have one of the best Extra Corporeal Photopheresis (ECP) programs in the state of Michigan that provides cutting-edge therapies to transplant patients with graft-vs.-host disease (GVHD).

This center has been performing allogeneic transplants since 1990 and has been an NMDP/Be The Match transplant center since September 1994.

Attending physicians

Adult - Sarah Anand, Monalisa Ghosh, Darren King, John Maciejewski, John Magenau, Attaphol Pawarode, Dan Peltier, Pavan Reddy, Mary Riwes

Pediatric - Ghada Abusin, Sung Choi, Mark Vanderlugt, Gregory Yanik

Transplants performed

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on

Adult and pediatric

Other programs and services

Our program has been at the forefront of the development of CAR T-cell therapies for the past several years. Our program was 1 of 13 programs that participated in the CAR-T licensing trial for childhood ALL and 1 or 20 programs participating in the pivotal trial that led to FDA approval of diffuse large cell lymphoma for adults. Our BMT program has been the first in the state of Michigan to offer all the currently FDA-approved CAR T-cell therapies through Kymriah (Novartis) and Yescarta (Kite). Our Cellular Immunotherapy program is also very active in research efforts that include various CAR's, tumor cell vaccines, and cell-based therapies that utilize stem cells to create new tissues and gene therapies.

Patient Support Services are available throughout the course of the patient's treatment for BMT and CAR-t cell therapies: Patient and Family Research Center, Practical Assistance Services, Complimentary Therapy Programs ,Psych Oncology Program, Counseling and Spiritual Services, Community Programs, Patient and Caregiver Support Services, BMT Nutritional Services, Fertility Services and easy communication with our medical staff via Michigan Medicine patient portal.


About the center

Overview

The University of Michigan’s BMT program averages 250 transplants each year-making us one of the largest programs in the state of Michigan. Our program is patient-focused, research-driven and internationally recognized for expertise in transplantation. Our Adult & Pediatric program has maintained FACT accreditation for the past 20 years and maintains a multidisciplinary approach to treating our BMT patients. Our medical teams are comprised of physician, nurse coordinators, physician assistants, social work, and pharmacists working together with insurance and financial teams to provide each patient the best care all in one hospital. In addition, we also have one of the best Extra Corporeal Photopheresis (ECP) programs in the state of Michigan that provides cutting-edge therapies to transplant patients with graft-vs.-host disease (GVHD).

This center has been performing allogeneic transplants since 1990 and has been an NMDP/Be The Match transplant center since September 1994.

Attending physicians

Adult - Sarah Anand, Monalisa Ghosh, Darren King, John Maciejewski, John Magenau, Attaphol Pawarode, Dan Peltier, Pavan Reddy, Mary Riwes

Pediatric - Ghada Abusin, Sung Choi, Mark Vanderlugt, Gregory Yanik

Transplants performed

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on

Adult and pediatric

Other programs and services

Our program has been at the forefront of the development of CAR T-cell therapies for the past several years. Our program was 1 of 13 programs that participated in the CAR-T licensing trial for childhood ALL and 1 or 20 programs participating in the pivotal trial that led to FDA approval of diffuse large cell lymphoma for adults. Our BMT program has been the first in the state of Michigan to offer all the currently FDA-approved CAR T-cell therapies through Kymriah (Novartis) and Yescarta (Kite). Our Cellular Immunotherapy program is also very active in research efforts that include various CAR's, tumor cell vaccines, and cell-based therapies that utilize stem cells to create new tissues and gene therapies.

Patient Support Services are available throughout the course of the patient's treatment for BMT and CAR-t cell therapies: Patient and Family Research Center, Practical Assistance Services, Complimentary Therapy Programs ,Psych Oncology Program, Counseling and Spiritual Services, Community Programs, Patient and Caregiver Support Services, BMT Nutritional Services, Fertility Services and easy communication with our medical staff via Michigan Medicine patient portal.


Overall center survival


Patient survival information for this center

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2015, 2016, 2017, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 277 patients.

The actual 1-year survival of these patients is 72.1%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 65.9% and 76.0%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

Number of adult transplants

Total adult transplants


418

Transplants reported (From January 1, 2017 to December 31st, 2018 as reported by the centers)

Marrow PBSC Cord blood Total
Allogeneic
Related donor 11 69 0 80
Unrelated donor 29 85 0 114
Total allogeneic 40 154 0 194
Autologous
Both marrow & PBSC
224
-- 224
Total combined
418 0 418

Number of pediatric transplants

Total pediatric transplants


67

Transplants reported (From January 1, 2017 to December 31st, 2018 as reported by the centers)

Marrow PBSC Cord blood Total
Allogeneic
Related donor 11 1 1 13
Unrelated donor 13 1 10 24
Total allogeneic 24 2 11 37
Autologous
Both marrow & PBSC
30
-- 30
Total combined
56 11 67

Transplants by disease

All diseases

Number of transplants by age reported from January 1, 2017 to December 31st, 2018 (includes marrow, PBSC and cord blood)

0-18 19-44 45-64 65+ Total
Related 13 22 42 16 93
Unrelated 24 29 57 28 138
Autologous 31 37 115 71 254
Total 68 88 214 115 485

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.

Centers are not required to report autologous transplants so the numbers might be incomplete.

More information about transplants for this disease can be found:

Additional information

Transplant center resources

If you have transplant-related questions, please call the transplant center's direct phone number.

If you have questions about costs and financial services at this center, please call the transplant center's direct phone number.

Be The Match patient navigators

Patient navigators can answer your questions about choosing a transplant center and provide support and education to help you throughout your transplant journey.

Inside the United States: 1 (888) 999-6743

Outside the United States: 1 (763) 406-3410.
(Long distance or international charges may apply.)

Email: patientinfo@nmdp.org

Survivorship program


No survivorship program information is available. Contact the center for information about post-transplant care.